Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2016

View Archived Issues

H3 Biomedicine initiates phase I study of H3B-8800 in MDS, AML and CMML

FDA grants clearance for Alere i RSV rapid molecular test

FDA approves Pfizer's Troxyca ER

Celgene Quanticel Research describes novel JARID1A/1B inhibitor at ACS

ABCB6 is a genetic modifier of the severity of hereditary porphyria

AB Science patents atitumoral agents

Bayer Pharma discloses sGC activators

F12 and STC2 genes as independent prognostic factors in breast cancer

EMA accepts Portola Pharmaceuticals' MAA for Indexxa

FDA extends iGlarLixi NDA review following submission of additional information

Cancer Research Technology develops ENPP2 inhibitors

Chinese scientists present Nav1.7 channel blockers

Phase II results demonstrate clinical activity for venetoclax monotherapy in patients with AML

Rio Grande Neurosciences terminates binding letter agreement with Endonovo Therapeutics

PATH initiates phase I trial of MCV-5 meningococcal conjugate vaccine

Randox Biochip Array Technology allows rapid determination of ApoE4 status in plasma

Shionogi initiates phase III trial of S-649266 to treat carbapenem-resistant Gram-negative bacteria

Vaccinex's VX-15 gets FDA orphan drug designation for the treatment of Huntington's disease

PZM-21 is a potent, novel mu-opioid receptor agonist with reduced side effects

New phase II trial explores safety and immunogenicity of TSI-GSD-210 for Western equine encephalitis

FDA grants tentative approval to Supernus Pharmaceuticals' NDA for Trokendi

FDA accepts IND for Zymeworks' ZW-25

Nordic Nanovector announces completion of several arms in betalutin trial

Arca Biopharma randomizes 100th patient in GENETIC-AF clinical trial

Nutrinia and Morristown close deal to fund oral insulin trials